Details for New Drug Application (NDA): 022159
✉ Email this page to a colleague
The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
Summary for 022159
Tradename: | ORAVERSE |
Applicant: | Septodont Holding |
Ingredient: | phentolamine mesylate |
Patents: | 0 |
Pharmacology for NDA: 022159
Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for 022159
Suppliers and Packaging for NDA: 022159
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159 | NDA | Septodont, Inc. | 0362-0101 | 0362-0101-10 | 10 CARTRIDGE in 1 CARTON (0362-0101-10) / 1.7 mL in 1 CARTRIDGE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 0.4MG/1.7ML | ||||
Approval Date: | May 9, 2008 | TE: | RLD: | Yes |
Expired US Patents for NDA 022159
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription